Chair: Amir Lavaf, MD

Desert Regional Medical Center, Palm Springs, CA

Topic: Delivering GBM treatment in an outpatient setting

  • Dr. Lavaf shared the benefit of Optune as an "at-home treatment"
  • Dr. Lavaf also discussed support services such as nCompass that not only help facilitate starting and maintaining treatment, but are relevant in supporting patients who are using digital platforms as a means of "owning" their therapy with Optune

Watch a video of this webcast:

Chair: Jennifer Serventi, PA-C

University of Rochester Medical Center, Rochester, NY

Topic: Maintaining GBM treatment remotely with Optune

  • Ms. Serventi accentuated the importance of continuing treatment even during these stressful times
  • She also highlighted the benefits of telemedicine in helping patients:
    • Prevent and manage adverse events involving the skin
    • Achieve monthly usage goals

Watch a video of this webcast:

Chair: Matthew Ballo, MD

University of Tennessee, West Cancer Center, Memphis, TN

Topic: A case study in utilizing telemedicine for cancer management

  • Dr. Ballo led a discussion on remote cancer management with TTFields (Tumor Treating Fields)
  • He also discussed the benefits of treatment with TTFields in GBM & MPM and shared a case study from his practice
  • Dr. Ballo emphasized what nCompass services are available to help your patients using Optune

Watch a video of this webcast:

For any questions about Optune or how to utilize it in your practice, contact a Novocure representative or go to Optune.com/hcp.

Indications For Use

Optune® is intended as a treatment for adult patients (22 years of age or older) with histologically-confirmed glioblastoma multiforme (GBM).

Optune with temozolomide is indicated for the treatment of adult patients with newly diagnosed, supratentorial glioblastoma following maximal debulking surgery, and completion of radiation therapy together with concomitant standard of care chemotherapy.

For the treatment of recurrent GBM, Optune is indicated following histologically- or radiologically-confirmed recurrence in the supratentorial region of the brain after receiving chemotherapy. The device is intended to be used as a monotherapy, and is intended as an alternative to standard medical therapy for GBM after surgical and radiation options have been exhausted.

Optune Lua is indicated for the treatment of adult patients with unresectable, locally advanced or metastatic, malignant pleural mesothelioma (MPM) to be used concurrently with pemetrexed and platinum-based chemotherapy.

Important Safety Information

Contraindications

Do not use Optune in patients with GBM with an implanted medical device, a skull defect (such as, missing bone with no replacement), or bullet fragments. Use of Optune together with skull defects or bullet fragments has not been tested and may possibly lead to tissue damage or render Optune ineffective. Do not use Optune Lua in patients with MPM with implantable electronic medical devices such as pacemakers or implantable automatic defibrillators, etc.

Use of Optune for GBM or Optune Lua for MPM together with implanted electronic devices has not been tested and may lead to malfunctioning of the implanted device.

Do not use Optune for GBM or Optune Lua for MPM in patients known to be sensitive to conductive hydrogels. Skin contact with the gel used with Optune and Optune Lua may commonly cause increased redness and itching, and may rarely lead to severe allergic reactions such as shock and respiratory failure.

Warnings and Precautions

Optune and Optune Lua can only be prescribed by a healthcare provider that has completed the required certification training provided by Novocure®.

The most common (≥10%) adverse events involving Optune in combination with chemotherapy in patients with GBM were thrombocytopenia, nausea, constipation, vomiting, fatigue, convulsions, and depression.

The most common (≥10%) adverse events related to Optune treatment alone in patients with GBM were medical device site reaction and headache. Other less common adverse reactions were malaise, muscle twitching, and falls related to carrying the device.

The most common (≥10%) adverse events involving Optune Lua in combination with chemotherapy in patients with MPM were anemia, constipation, nausea, asthenia, chest pain, fatigue, medical device site reaction, pruritus, and cough.

Other potential adverse effects associated with the use of Optune Lua include: treatment related skin toxicity, allergic reaction to the plaster or to the gel, electrode overheating leading to pain and/or local skin burns, infections at sites of electrode contact with the skin, local warmth and tingling sensation beneath the electrodes, muscle twitching, medical device site reaction and skin breakdown/skin ulcer.

If the patient has an underlying serious skin condition on the treated area, evaluate whether this may prevent or temporarily interfere with Optune and Optune Lua treatment.

Do not prescribe Optune or Optune Lua for patients that are pregnant, you think might be pregnant or are trying to get pregnant, as the safety and effectiveness of Optune and Optune Lua in these populations have not been established.

Please click here to see the Optune Instructions For Use (IFU) for complete information regarding the device's indications, contraindications, warnings, and precautions.

Please click here to see the Optune Lua IFU for complete information regarding the device's indications, contraindications, warnings, and precautions.